Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma

Table 3

Treatment-emergent adverse events for the two groups.

Treatment toxicities	Number of patients (%)
	Group 1 ()	Group 2 ()	Total ()
Grades 1-2
Neutropenia or leukopenia	22 (44.9%)	13 (65%)	35 (50.7%)
Anemia	15 (30.6%)	8 (40%)	23 (33.3%)
Thrombocytopenia	11 (22.4%)	7 (35%)	18 (26.1%)
Infection	0	1 (5%)	1 (1.4%)
Nausea or emesis	25 (51.0%)	9 (45%)	34 (49.3%)
Fatigue	31 (63.3%)	13 (65%)	44 (63.8%)
Constipation	19 (38.8%)	10 (50%)	29 (42.2%)
Others	5 (10.2%)	2 (10%)	7 (10.1%)
Grades 3-4
Hematologic toxicities	8 (16.3%)	7 (35%)	15 (21.7%)
Nonhematological toxicities	0	1 (5%)	1 (1.4%)